Anastassia Amaro, MD

Obesity Medicine, Diabetes, Endocrinology
Accepting new patients
Sees patients age 18 and up
Penn Endocrinology Perelman
View 3 additional locations
Headshot of Anastassia Amaro, MD
Penn Medicine Provider

About me

  • Medical Director, Penn Metabolic Medicine
  • Professor of Clinical Medicine (Endocrinology, Diabetes and Metabolism)

My education and training

  • Medical School: First Moscow Sechenov Medical Institute
  • Residency: First Moscow Sechenov Medical Institute
  • Residency: Advocate Lutheran General Hospital
  • Fellowship: Barnes-Jewish Center for Outpatient Health

Reviews

Average Rating

429 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
she is very knowledgeable with very good interpersonal skills
Anonymous
March 2026
very thorough
Anonymous
March 2026
dr amaro listens and includes me in decision making.
Anonymous
March 2026
she's great!

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Amaro is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Authors: Ryan R. Armbruster, Neil E. Wilson, Yvette Frimpong, Anne Cappola, Anastassia Amaro, Ravinder Reddy CrCEST Measures OXPHOS Improvement and Creatine Decrease following GLP-1 induced weight loss at 7T with 1H-MRS , Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition: 2026


Tang H, Zhang B, Lu Y, Lu Y, Amaro A, Lu Y, Wolk DA, Chen Y. Patterns and Trends of Glucose-Lowering Therapy in Alzheimer's Disease and Related Dementias , Diabetes Obesity Metabolism: 2026


Salvatore M, Zhang B, Tang H, Lu Y, Zhang D, Zhou T, Lu Y, Amaro A, D Ritchie M, Chen Y. Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us. , Naure Communications: 2026


Ryan R. Armbruster, Neil E. Wilson, Aylin Ergin, Anne Cappola, Anastassia Amaro, Ravinder Reddy Lipid and Acetyl Carnitine Differences measured before and after GLP-1 induced weight loss at 7T with 1H-MRS , Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition: 2026


Conte, C., Amaro, A. Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes , Curr Diab Rep : 2026


Wonkyung Choi, Young-Hoon Nho, Liming Qiu, Andrew Chang, Gustavo Campos, Robert L. Seilheimer, W. Bryan Wilent, David Bakalov, Nida Firdous, Marie Kerr, Disha Joshi, Gabriella Maze, Uros Topalovic, Daniel Batista, Nanthia Suthana, Anastassia Amaro, Matthew R. Hayes, Iahn Cajigas, Mario Cristancho, Kelly C. Allison, Bijan Pesaran, Katherine W. Scangos, Joshua I. Gold, Thomas A. Wadden & Casey H. Halpern Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide , Nature Medicine: 2025


Marianne Riordan, Anastassia Amaro Glucagon-Like Peptide-1 Receptor Agonists in Post-Bariatric Hypoglycemia: A Retrospective Chart Review , 32nd European Congress on Obesity: 2025


Caturano A, Amaro A, Berra CC, Conte C. Sarcopenic obesity and weight loss-induced muscle mass loss , Curr Opin Clin Nutr Metab Care: 2025


Emily Gleason, BA Lindsay Levine, BA ∙ Iris T. Lee, MD MSCE ∙ Nathanael Koelper, MPH ∙ Anastassia Amaro, MD ∙ Anuja Dokras, MD, MHCI, PhD Effect of Glucagon-Like Peptide 1 Agonist Medications on Weight Loss in Patients with and Without Polycystic Ovary Syndrome , Fertility and Sterility: 2025


Ariana M Chao 1, Simeon Taylor 2, Molly Moore 3, Anastassia Amaro 4, Thomas A Wadden 3 Evolving Approaches for Pharmacological Therapy of Obesity , Annu Rev Pharmacol Toxicol : 2025